MedTrace Logo

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older

NCT06961721 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2025-05-08

No results posted yet for this study

Summary

To evaluate the immunogenicity 42 days after vaccination with the live attenuated herpes zoster vaccine.

To evaluate the safety of the live attenuated herpes zoster vaccine.

Conditions

  • Prevention of Herpes Zoster

Interventions

BIOLOGICAL

Herpes Zoster Vaccine, Live

assigned to the vaccine group and placebo group in a 2:1 ratio.

BIOLOGICAL

Placebo

assigned to the vaccine group and placebo group in a 2:1 ratio.

Sponsors & Collaborators

  • Inner Mongolia Center for Disease Control and Prevention

    collaborator UNKNOWN

  • Center for Disease Control and Prevention, Fujian

    collaborator OTHER

  • Changchun BCHT Biotechnology Co.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-31
Primary Completion
2025-07-31
Completion
2025-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06961721 on ClinicalTrials.gov